Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Funobactam (XNW4107) in Healthy Adults
NCT04482569Phase 1Completed
- Sponsor
- Evopoint Biosciences
- Start
- Jul 2020
- Primary completion
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of pibozobactam in gram-negative bacterial infections (3 arms), sponsored by Evopoint Biosciences. Primary endpoint: Number of participants experiencing adverse events. Started Jul 2020; status: completed.
02
Drugs
pibozobactam
03
Conditions
gram-negative bacterial infections
Beyond the preview
Go deeper on NCT04482569.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04482569.